Investor Relations · 2026
Investors
Nightbox LLC is raising a pre-seed round in Q3 2026 to fund in vivo validation across three syngeneic murine tumor models, the wet-lab scientific lead hire, and the FDA pre-IND briefing book. Current stage is computational only — no in vivo or clinical data exists. A follow-on seed will open after wet-lab validation lands. Full data room on request.
Round terms (target)
| Round | Pre-seed |
| Target close | Q3 2026 (pre-seed); follow-on seed targeted post-in-vivo (H1 2027) |
| Target raise | $3M – $5M (pre-seed) |
| Use of proceeds | In vivo validation, 3 syngeneic models (≈60%) · wet-lab scientific lead hire (≈20%) · pre-IND meeting prep (≈15%) · regulatory consultant (≈5%) |
| Cap table | 100% founder-owned. $0 raised to date. No prior outside capital. |
| Current evidence | Computational only. AlphaFold/Rosetta structural validation, PK-PD model, MICA/B selectivity atlas. No in vivo, no human, no peer-reviewed data yet. |
| Exit thesis | Strategic acquisition by US pharma post-Phase 2 |
Three pillars compound
Investors usually back one thesis at a time. Nightbox runs three deep-tech pillars on a shared substrate, each de-risking the others:
| 🧬 Biotech | NKG2D-LIF6 chimera. Provisional patent filed. Strategic-acquisition exit thesis. |
| ⚡ Compute | UniGPU runtime. 47 TFLOP/s WMMA on consumer AMD. SBIR Phase II / DARPA / DIU transition. |
| 🦆 AI agent | SilverDuck local-first stack. NB-R14B LLM (Apache 2.0). Federal classified-environment fork roadmap. |
| 🛡️ Substrate | Cyber Golden Dome — defensive infrastructure underlying all three. Federation upside is asymmetric: zero-cost-to-federal-government federal-recognition path with potential CISA tier badge / OSTP endorsement / Treasury BFS letter. |
Capital deployed to any single pillar materially improves the others (shared compute, shared infrastructure, shared compliance posture). Pre-seed is fundable on biotech alone; the cyber substrate is the asymmetric upside.
Why now
- NKG2D-targeted oncology is clinically validated — Fate Therapeutics has IND clearance for FT536; multiple Phase I trials show signal.
- Single-construct gene therapy bypasses CAR-T manufacturing complexity entirely.
- Clean intellectual property whitespace on the specific NKG2D-LIF6 chimera.
- AI-augmented R&D operating model — production Claude-based agent stack on Vercel Edge, AlphaFold3 + RoseTTAFold structural pipeline, PyMOL + SnapGene construct design, custom prompt-router with NFKC normalization and 22-pattern injection scanner. Methods and code public under CC BY 4.0.
- Federal procurement environment in 2026 favors domestic dual-use biotech with national security relevance.
- Cyber Golden Dome v1.0 shipped 2026-05-09. First defense doctrine in any domain that produces net U.S. federal revenue per intercept. Reference implementation live; federation registry permissionless. Federal-recognition pathway active.
Public traction artifacts
Every claim below is independently verifiable from a public URL. No data-room access required.
- 14/14 empirical pentest matrix PASS — attested by Claude Opus 4.7 (1M context), reproducible commands at /.well-known/cryptographic-contact.json
- 14 DNSSEC-anchored TXT records validating every published spec — verify with
dig +short TXT _poq.nightboxllc.com - 13 federal-compliance manifests — single discovery point at /.well-known/manifest-index.json
- 31-item federal-frameworks self-attestation grid — visualized at /capabilities
- SAM.gov registered (UEI
UHCAB6UXXKF2) — directly verifiable at sam.gov - Wikidata cross-attestation — organization Q139590659, founder Q139590669, NKG2D-LIF6 chimera Q139590736
- 14B-parameter NB-R14B LLM (Apache 2.0) — proprietary in-house weights for the SilverDuck pillar
- Open source at github.com/nightbox-llc — Apache 2.0 (code) + CC-BY-4.0 (doctrine)
Materials available on request
- Seed deck (current version)
- Full freedom-to-operate analysis
- In silico validation report and methods
- Construct architecture and selectivity model
- Provisional patent draft (under NDA)
- Financial model and use-of-proceeds breakdown
- Founder background and references
Public materials
Get the data room
Send a brief note (firm, focus areas, ticket size, lead-vs-follow) to investors@nightboxllc.com. We typically share access within 24 hours and follow up to schedule a 30-minute working call.